SWE Theranostic Syringe Shields

< back to products

In The News

Biodex is often cited in news articles discussing industry trends, new technology and advancements.  There are also times when we find interesting news articles that we like to share with our customers. Outlined below are periodicals where Biodex has been mentioned, corporate press releases, and other relevant industry news. 

Biodex Medical Systems, Inc. and SWE today announced a strategic partnership expanding the global theranostics and nuclear medicine offering in terms of availability and latest market innovation. A natural synergy combines SWE’s new, highly efficient product design with the expansive network of global distributors and expertise of Biodex.

October 12, 2019 – The  absolute revolution of  nuclear medicine with the emergence of theranostics is forcing all stakeholders involved in the process to come up with new, outside-the-box thinking. Reducing exposure, ensuring safe manipulations, reducing weight, size and footprint for transportation while remaining efficient and ergonomically on point is no easy concept. SWE and Biodex joining forces provides innovative solutions that will address these paradigms increasing throughput, saving cost and comply with strict regulations such as USP 797/825. SWE helps reinforce the Biodex commitment to streamline, facilitate and expand the use of theranostics and other radionuclide therapies, having a direct impact on patient outcome as stated earlier this year. >>

Leader in nuclear medicine and molecular imaging solutions, Biodex is providing a comprehensive approach for current and future theranostics and targeted therapies. Their wide range of products is solving the daily challenges of cancer diagnosis and treatment management in academic, research, industry and clinical settings across the globe. 

May 29, Shirley NY – According to the International Agency for Research on Cancer of the World Health Organization, the number of incident cases of cancer exceeded 18 million in 2018 and could potentially double by 2040. With a gigantic economic impact (total annual cost of cancer in 2010 reaching an approximate US $1.16 trillion) and strain on the healthcare space, Biodex is determined to streamline, facilitate and expand the use of theranostics and other radionuclide therapies having a direct impact on patient outcome. >>

 

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Read More